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INTRODUCTION 
 
The proportion of elderly people is progressively rising 
throughout  the  world,  with  the  most  pronounced 
increase in the developed  world. Elderly people (>65 
years old) are expected to comprise greater than 20% of 
the  world’s  human  population  by  2050  [1]  .  This 
increase  is  posing  major  challenges  for  healthcare 
systems, as aging is associated with marked increases in 
a number of diseases, including most types of cancers 
[2-4].  With  more  than  80%  of  human  cancers  being 
diagnosed after the age of 50 [5], aging represents the 
single  most  important  prognostic  factor  for  many 
cancers,  including  lung,  breast,  colon,  prostate,  and 
certain leukemias [3, 6, 7]. 
 
Since  the  original  proposal  by  Peter  Nowell  [8],  the 
cancer  research  community  has  widely  accepted  the 
idea  that  initiation  and  progression  of  tumors  are  the 
results  of  clonal  evolution,  where  increased  genetic 
instability fuels the selection of clones with  
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progressively  increased  fitness.  Historically,  the 
predominant  focus  in  conceptualizing  this  clonal 
evolution  has  been  on  mutations,  perhaps  due  to  the 
implicit  assumption  that  once  a  relevant  oncogenic 
mutation occurs in a relevant cell type, clonal expansion 
will  inevitably  follow.  However,  unless  somatic 
evolution of cancer cell populations represents a special 
case,  it  should  follow  the  same  Darwinian  model  as 
evolutionary  processes  in  populations  in  Nature, 
whereby  fitness  is  context-dependent  rather  than 
absolute and the “winners” in the evolutionary game are 
determined by the interplay between diversification of 
heritable  types  and  environment-dependent  selection 
forces  (see  Box  1  for  definitions).  Indeed,  a  growing 
body  of  evidence  suggests  that  the  fitness  effects  of 
oncogenic alterations are highly context dependent [9-
11]  and  that  Darwinian  evolution  is  a  more  accurate 
representation  of  somatic  evolution  of  cancers  than 
linear step-wise mutation-centric models [12, 13]. 
Aging-associated changes in hematopoiesis and leukemogenesis:   
What’s the connection? 
 
Curtis J. Henry
1, Andriy Marusyk
2 and James DeGregori
1 
 
1Department of Biochemistry and Molecular Genetics, Integrated Department of Immunology, Department of 
Pediatrics, Program in Molecular Biology, University of Colorado Denver School of Medicine, Aurora, Colorado, USA 
2Department of Medical Oncology, Dana Farber Cancer Institute; Department of Medicine, Harvard Medical 
School, Boston, MA, USA 
 
Received: 6/20/11; Accepted: 6/27/11; Published: 7/2/11 
Correspondence toJames DeGregori, james.degregori@ucdenver.edu 
 
Copyright: © Henry, Marusyk and DeGregori. This is an open-access article distributed under the terms of the Creative Commons Attribution 
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited 
 
Abstract:Aging is associated with a marked increase in a number of diseases, including many types of cancer. Due to the 
complex and multi-factorial nature of both aging and cancer, accurate deciphering of causative links between aging and 
cancer remains a major challenge. It is generally accepted that initiation and progression of cancers are driven by a 
process of clonal evolution. In principle, this somatic evolution should follow the same Darwinian logic as evolutionary 
processes in populations in nature: diverse heritable types arising as a result of mutations are subjected to selection, 
resulting in expansion of the fittest clones. However, prevalent paradigms focus primarily on mutational aspects in 
linking aging and cancer. In this review, we will argue that age-related changes in selective pressures are likely to be 
equally important. We will focus on aging-related changes in the hematopoietic system, where age-associated alterations 
are  relatively  well  studied,  and  discuss  the  impact  of  these  changes  on  the  development  of  leukemias  and  other 
malignancies. 
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Organismal  fitness-  a  measure  of  reproductive  success  (the  ability  of  an  organism  to  pass  its  genes  on  to  future 
generations of that organism). 
 
Cell fitness- a measure of the ability of stem/progenitor cells of a certain epigenotype/genotype to pass this type on to 
subsequent cell generations. For discussions here, we are concerned with the fitness of cells that maintain replicative 
potential. Cell fitness is in some ways a relative parameter, and dependent on the fitness of competing cells. Thus, the 
relative representation of a particular clone within a progenitor cell pool is proportional to its fitness.  On the other hand, 
the fitness of stem and progenitor cells should also be comparable across individuals of different ages or genotypes, even 
if measurement of this relative fitness requires that these cells be placed in competition, such as following transplantation 
into a common host.  
 
Adaptive- increases fitness (e.g.  a mutation that increases cellular fitness would be adaptive). 
 
Mutation- we will often refer to heritable epigenetic and genetic mutational changes generally as “mutations”. 
 
Adaptive landscapes- the potential epigenetic and genetic changes that could alter the fitness of a cell population. 
 
Strong  associations  between  aging  and  cancer  are 
traditionally used to support the mutation-centric view 
of clonal evolution of cancers: aging leads to build up of 
random mutations, and since a) some of these random 
mutations are expected to activate cellular oncogenes or 
silence  suppressor  genes  and  b)  transformation  is 
thought  to  require  cooperation  between  several 
oncogenic events, aging should translate into increased 
risk of cancer initiation [14]. On the other hand, aging is 
also  associated  with  substantial  changes  both  inside 
cells and in the cellular environment. In principle, these 
changes are likely to modify  the ability of oncogenic 
mutations to drive clonal expansion. In fact, some of the 
age-related changes such as increased inflammation and 
decreased  immune  surveillance  have  been  clearly 
implicated  in  carcinogenesis.  In  addition,  intracellular 
changes such as telomere shortening as well as growth-
inhibitory  changes  in  the  microenvironment  could 
create a scenario for a strong selection for “oncogenic 
resistance  to  growth  inhibitory  conditions”  [15].  We 
have  previously  proposed  an  Adaptive  Oncogenesis 
Hypothesis  (Box  2):  populations  of  healthy 
young/progenitor  cells  possess  high  inherent  fitness 
with little “room for improvement” [11, 16]. However, 
as  cellular  fitness  drops  due  to  cell-autonomous  age-
related changes or alterations in the microenvironment, 
certain mutations and epigenetic changes could alleviate 
the defects, leading to stronger selective expansion of 
the mutant clones. Therefore, the causal links between 
aging and cancer most likely includes both mutational 
components (diversification of heritable types through 
random mutations and heritable changes) and selection 
components (changes both inside and outside the cells 
that alter the adaptive landscape) (Figure 1). 
 
 
The  effects  of  aging  are  highly  complex  and  span 
organismal,  systemic  and  cellular  levels  [17].  Cancer 
development is similarly complex.  Thus it would be 
naïve to expect a simple relationship between the two 
(Figure  1).  Numerous  changes  in  aged  individuals, 
including changes in cell type distributions in the bone 
marrow microenvironment, increased inflammation and 
decreased fitness of progenitor cell populations, should 
substantially impact on the expansion of oncogenically 
altered hematopoietic progenitor cell clones. Together 
with  increased  epigenetic/genetic  diversity,  these 
changes should increase the risk of cancers in old age. 
In  this  review  we  will  focus  on  the  hematopoietic 
system,  as  age-related  changes  in  hematopoiesis  are 
very  well  documented  for  both  humans  and  mice  [2, 
18].  We  will  review  age-related  changes  in  the 
hematopoietic  system  and  discuss  how  these  changes 
might impinge on hematopoietic and non-hematopoietic 
malignancies. 
 
Aging Hematopoiesis 
 
One  of  the  more  notable  age-related  changes  is 
hematopoietic  and  specifically  immunological  decline 
[1,  21-25]  (Figure  3).    Maintaining  the  health  of  the 
growing elderly population is limited by the associated 
decline  in  immune  function  [23-25],  impairing 
responses  to  pathogens  and  reducing  vaccination 
efficacy.    Decreased  immune  function  is  not 
compartmentalized; reduced immune cell function (and 
in some cases cell numbers) has been observed in both 
the  myeloid  and  lymphoid  lineages  [23-25].  
Furthermore,  recent  studies  have  indicated  that  these 
functional reductions result at least in part from aging- 
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Box 2: Adaptive Oncogenesis Hypothesis: 
 
The most accepted explanation for the association between aging and cancer is that accumulating oncogenic mutations 
with age should facilitate cancer evolution [19].  Thus, according to this view, cancer development is limited primarily 
by the accumulation of oncogenic mutations (Figure 2, top). But just as species evolution is driven by both mutation and 
selection, altered selection pressures with age should also contribute to oncogenesis.  Thus, aged stem cell pools in an 
aged microenvironment should present a different “adaptive landscape” relative to young.  
 
We have proposed that declining stem and progenitor cell fitness, whether due to aging or other insults, should increase 
selection for mutations (or epimutations) that are adaptive (i.e. that improve fitness) [10, 11, 16]. A change in the 
adaptive landscape should lead to selection for cells harboring advantageous traits (adaptive to the altered landscape), 
and these cells should be preferentially selected within their particular niche (Figure 2). Aging or other insults move 
cells away from parameters that contribute to optimal fitness, thus creating opportunities for mutational adaptation.  The 
acquisition of particular oncogenes in an aged background could be adaptive by either correcting or circumventing 
deficiencies in old cells.  In addition, particular oncogenic mutations may render a cell resistant to aging-associated 
insults, such as chronic inflammation that promotes cellular senescence or apoptosis due to increased reactive oxygen 
species (ROS) production. 
 
In contrast, a young healthy progenitor cell pool should be resistant to the fixation of trait-altering mutations.  The 
evolution  of  long-lived  multicellular  organisms  (like  vertebrates)  has  necessitated  the  acquisition  of  potent  tumor 
suppressive mechanisms, but this selection was limited to individuals who were likely to contribute to future generations 
[11]. Consequently, selection against cancer and other unpleasant manifestations of aging in the elderly has been quite 
weak during vertebrate evolution.  As a simple example, mice in the wild rarely live past one year, and most age-
associated tissue decline and increased cancer incidence occur well past this natural lifespan [20]. Thus, investment in 
tissue maintenance or tumor suppression beyond their natural lifespan would have required an investment of precious 
energy early in life, which could be better allocated towards survival and reproduction in youth. While George Bernard 
Shaw may have considered that “Youth is wasted on the young”, each species has ensured that youthful fitness is 
maximized  for  reproductive  success.  Stem  cell  fitness,  which  contributes  to  youthful  robustness,  will  enhance 
reproductive success by limiting diseases of aging, including cancer.  
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Figure 1.  Proposed Links between Aging and Cancer.  See text for details. 
 associated  defects  in  hematopoietic  stem  cell  (HSC) 
function,  which  are  transferred  to  the  their  lineage-
committed progeny [23, 25].  The causes of the aging-
associated  decline  in  HSC  and  hematopoietic  cell 
function  are  still  open  for  debate.  Hematopoietic  cell 
aging  is  associated  with  accumulating  epigenetic  and 
genetic  changes,  changes  in  the  microenvironment  of 
both  immature  and  mature  hematopoietic  cells,  and 
systemic changes such as inflammation.  The relative 
contributions  of  these  changes  to  altered  HSC  and 
mature  hematopoietic  cell  function  are  still  being 
explored.    Moreover,  a  number  of  mechanisms  have 
been proposed for how these changes might contribute 
to increases in age-associated cancers (Figure 1), and 
this review will focus on the multiple ways that aging 
could promote hematopoietic malignancies. 
 
Hematopoiesis, which takes place in the bone marrow, 
is  the  production  of  all  blood-derived  cells  from 
pluripotent HSC.  Most of our current knowledge on the 
impact of aging on HSC function comes from studies 
using  mouse  models  [23,  25-28].    These  studies 
implicate both cell intrinsic and cell extrinsic factors  
towards  impairmentsof  age-dependent  alterations  in 
HSC  behavior,  although  within  animals  both  intrinsic 
and extrinsic influences are tightly interwoven and are 
sometimes  difficult  to  disentangle  [18].  Extrinsic 
factors,  including  changes  in  niche  composition  and 
hormone  production,  have  been  postulated  to  play  a 
major role in declining HSC function with age [18, 29].  
In vivo, multiphoton intravital microscopic analysis of 
HSC in the bone marrow of young and old mice has 
revealed  that  old  HSC  reside  further  away  from  the 
endosteum than young HSC progenitors, indicating age-
related  extrinsic  changes  in  niche  composition  that 
could impact HSC function [30].  HSC normally reside 
in the HSC hypoxic endosteum microenvironment [30-
32].  The effects of hypoxia on HSC function are just 
beginning to be delineated. It has been postulated that 
hypoxia  regulates  HSC  self-renewal  by  promoting 
optimal  turnover,  which  would  limit  potential 
accumulation of damage [32, 33], contributing to cell-
intrinsic  changes.    Thus,  residing  further  away  from 
endosteum,  by  increasing  oxidative  damage  to  DNA, 
could increase the mutational load in HSC. In addition, 
it  is  believed  that  hypoxia  limits  the  flow  of  extra-
cellular fluids into the endosteum niche, which reduces 
HSC exposure to potentially hazardous toxins and pro-
inflammatory cytokines, some of which are known to be 
tumor  promoting  [32-34]  .    Indeed,  aging  in  mice  is 
associated  with  increased  detection  of  DNA  strand 
breaks  in  HSC  [35],  and  it  is  likely  that  increased 
mutational load contributes to increased initiation and 
progression of cancers in the elderly (whether mouse or 
human). 
 
Moreover,  another  consequence  of  increasing 
mutational  load  in  HSC  (as  in  other  stem  cell  types) 
should be the reduction in stem cell fitness, as DNA 
damage is more likely to negatively impact on cellular 
functions than improve them. Indeed, aging-related, cell 
autonomous  changes  have  also  been  shown  to 
contribute to altered HSC function [28, 36-38]. When 
highly purified long-term HSC (LT-HSC) from young 
or  old  mice  are  used  to  reconstitute  young  irradiated 
recipient mice, old LT-HSC are 2 to 4-fold less efficient 
at  reconstitution  per-HSC,  and  their  production  is 
skewed  in  favor  of  myelopoiesis,  with  accompanying 
reductions  in  lymphopoiesis  (to  be  dealt  with  below) 
[27, 36, 38-40]. Thus, as defined above, old HSC are 
less “fit”, in that young competitors are better able to 
contribute  to  hematopoiesis.  Aged  mouse  HSC  also 
exhibit  decreased  homing  and  engraftment  [39,  41]. 
And as described above, altered stem cell fitness should 
increase  selection  for  adaptive  oncogenic  mutations 
(Figure  2),  increasing  the  chances  that  stem  cells 
bearing  particular  oncogenic  mutations  expand  within 
competitive  HSC  pools  in  an  aged  bone  marrow 
microenvironment.    Therefore,  aging-associated 
alterations  in  HSC  localization  and  mutational  load 
should  not  only  increase  the  frequency  of  oncogenic 
mutations,  but  selection  for  particular  oncogenic 
mutations. 
 
Finally,  the  hematopoietic  system  may  attempt  to 
compensate for decreased HSC function (and decreased 
production rates for mature progeny) by increasing the 
size  of  the  HSC  compartment,  as  indicated  by  the 
observation  that  the  number  of  phenotypic  HSC  in 
C57Bl/6 mice increases with age [36, 38, 39, 42-44]. 
Such increased homeostatic mechanisms, both through 
increased  cytokine  levels  and  perhaps  increased 
turnover  rates  for  HSC  and  other  progenitors,  should 
contribute  to  higher  chances  for  mutation  fixation. 
Larger numbers of HSC should also increase the target 
size for oncogenic mutations.  However, increased HSC 
numbers have not been observed in all mouse strains; 
BALB/c  and  DBA/2  do  not  show  an  age-dependent 
increase in the numbers of phenotypic HSC [45-47], but 
may  still  experience  other  homeostatic  mechanisms.  
Although the effects of aging on human HSC have not 
been as extensively studied, human HSC function also 
appears to be affected by aging given the observation 
that the proliferative potential of human HSC declines 
with  age  [48].    In  addition,  bone  marrow  from  older 
humans  is  less  efficient  at  reconstituting  recipients 
when compared to the reconstitution capacity of bone  
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marrow  derived  from  younger  patients  [49].    In 
summary,  based  on  experiments  in  mice  and  more 
limited observations in humans, it is clear that a number  
of age-associated alterations in the HSC compartment, 
due  both  to  extrinsic  and  intrinsic  factors,  could 
contribute  to  increased  frequencies  of  hematopoietic 
malignancies in the elderly. 
 
Aging Innate Immunity 
 
In  aged  mice,  it  has  been  demonstrated  that  a 
developmental shift occurs, with reduced lymphopoiesis 
in favor of greater myelopoiesis.  Microarray analyses 
of  HSC  isolated  from  old  mice  reveals  a  gene 
expression  profile  consistent  with  this  age-dependent 
bias towards production of myeloid cells [36, 38].  The 
myeloid  bias  appears  to  be  at  least  in  part  cell-
autonomous, as adoptive transfer of young and old HSC 
into young, irradiated recipients recapitulates the age- 
 
 
 
 
 
 
 
 
 
dependent bias towards myelopoiesis [1, 36, 50].  This 
bias appears to be at least in part mediated by a shift  
towards greater frequency of myeloid-biased relative to 
lymphoid-biased  HSC  [42,  51,  52],  and  these 
differentially  biased  HSC  can  now  be  prospectively 
isolated and shown to transfer their developmental bias 
to recipient mice [37, 53, 54].  It is important to note 
that  while  myelopoiesis  becomes  favored 
overlymphopoiesis in old mice, myeloid progenitors are 
not “more fit” relative to young.  Myeloid and B-cell 
progenitors appear to compete for common niches [55], 
and mouse and human myeloid progenitors exhibit age-
dependent  reductions  in  progenitor  activity  [56,  57], 
while  mouse  B-progenitors  show  even  greater 
reductions  in  function  (thus,  providing  myelopoiesis 
with a relative advantage).  Moreover, elderly humans 
exhibit  decreased  developmental  potential  for  both 
lymphoid and myeloid progenitors [26, 57]. 
 
Figure 2  Conventional and Adaptive Oncogenesis Models for Tumorigenesis.  Conventional View (top): Aging primarily 
contributes  to  increased  cancers  by  facilitating  the  accumulation  of  oncogenic  mutations  (red  cells),  including  activating 
mutations in oncogenes or genetic/epigenetic inactivation of tumor suppressor genes.  Adaptive Oncogenesis Model (bottom): 
The ability of an oncogene to induce cancer is context specific.  In a healthy population, the ability of cells to effectively 
compete for niche space is high due to optimal progenitor cell fitness.  Thus, this competition is inherently tumor suppressive.  
However, if cellular fitness decreases as a result of aging or environmental insults, the acquisition of an oncogenic mutation 
could be adaptive due to its ability to correct or circumvent defective cellular function.  In this context, these cells would be 
selected for leading to carcinogenesis (oncogenically mutated and cancer cells are shown in red). 
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documented  in  dendritic  cells  (DC),  neutrophils,  and 
macrophages  (Figure  3)  [23,  58].    DC  are  the 
professional  antigen  presenting  cells  of  the  immune 
system,  and  are  the  principle  cells  responsible  for 
priming  naïve  CD4
+  and  CD8
+  T  cells  [23].    The 
potency of DC as primers of naïve T cells declines with 
age [23].  This decrease has been shown to result from 
reduced migration of DC to secondary lymphoid organs 
following  stimulation  and  defective  antigen  uptake, 
which results in decreased presentation to naïve T cells.  
 
 Natural killer (NK) cells, which protect against tumors 
and virally infected cells, are also impacted by the aging 
process in humans [23].   While their numbers actually 
increase  with  age  (despite  a  reduced  proliferative 
response to IL-2), their cytolytic potential decreases in 
aged populations.  Aging-associated reductions in DC 
and NK function may contribute to increasing cancer 
incidence  with  age  due  to  decreased  activation  of 
cancer-specific  T  cells  by  DC  and  impaired  NK 
mediated tumoricidal activity. 
 
 
 
 
In addition to the decreased innate cellular function that 
accompanies  aging,  older  humans  typically  present  a 
subclinical  inflammatory  status  termed  “inflamm-
aging”,  which  is  characterized  by  increased  tumor 
necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and 
interleukin-1β (IL-1β) in the plasma [23, 59].  Inflamm-
aging may also contribute to alterations in HSC with 
age [38, 53]. The increase in the circulating levels of 
inflammatory  cytokines  reflects  cell  autonomous 
changes  in  myeloid  gene  expression  resulting  in 
microenvironmental  changes  that  could  favor  tumor 
initiation  and  progression  [23].  Indeed,  chronic 
inflammation  is  a  well  defined  contributor  to 
tumorigenesis,  with  tumor  associated  macrophages 
(TAMs) playing a key role in driving tumorigenesis 
 
 
 
 
[59].  The cytokines produced by these cells, such as 
TNF-α, could influence cancer progression both by  
promoting  proliferation  of  oncogenically  initiated  or 
more  advanced  tumor  cells  and  by  inducing  death  of 
non-malignant  cells  (thus  stimulating  compensatory 
proliferation) [34, 60].  Inflammation may also create a 
hazardous microenvironment, with increased ROS and 
cell  death,  thus  promoting  selection  for  oncogenic 
events that confer resistance or are otherwise adaptive 
to  this  altered  microenvironment.  Thus,  aging-
associatedalterations in the innate immune system not 
only increase susceptibility to pathogens, but may also 
be critical in the evolution of many cancers, which can 
be promoted by inflammatory mediators. 
 
 
Figure 3. Alterations in the hematopoietic system associated with aging.  See text for details. 
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Age-associated  impairment  of  the  adaptive  immune 
system, which is composed of T cells and B cells, is 
observed in both mice and humans (Figure 3) [1, 27], 
and  could  impact  cancer  development  in  several 
respects.  In mice, the production of naïve CD4
+ T cells 
(T helper cells) declines with age [61].  CD8
+ T cell 
function also declines with age [23].  Specifically, naïve 
CD8
+ T cells isolated from aged individuals proliferate 
less when stimulated with IL-2, and their expansion and 
differentiation  into  effector  T  cells  upon  antigenic 
stimulation is reduced when compared to naïve CD8
+ T 
cells isolated from young individuals.  Although cell-
autonomous  changes  in  HSC  also  contribute  to  age-
associated  reductions  in  T-lymphopoiesis  [62], 
reductions  in  the  numbers  of  T  cells  are  mainly 
attributed to thymic involution that occurs with aging 
[1, 61].  Aging-associated changes in the thymus lead to 
a  decline  in  functional  cortex  and  medulla,  which  is 
replaced by fat [21, 61].  Decreased T cell maturation in 
the thymus may actually contribute to reduced T-acute 
lymphoblastic  leukemia  (T-ALL)  incidence  in  the 
elderly  (T-ALL  is  primarily  a  childhood  cancer),  as 
substantially reduced T cell precursor numbers would 
reduce  the  target  population  for  acquisition  of 
oncogenic mutations. 
 
Aging-associated alterations in T lymphocyte numbers 
and  function  lead  to  increased  susceptibility  to 
pathogenic  infections  and  a  decreased  ability  to 
effectively  vaccinate  the  elderly;  however,  the 
importance of T lymphocytes in the control of aging-
associated  cancers  is  somewhat  unclear.    Increased 
cancer incidence has been observed in immunodeficient 
mice, as well as humans that are immunocompromised, 
such  as  for  Karposi’s  sarcoma,  non-Hodgkin’s 
lymphoma, and cervical cancer in AIDS patients [63-
66].   Declining adaptive immunity could increase the 
incidence of these particular cancers because they are 
virally associated; however, for non-virally associated 
cancers,  the  role  of  the  adaptive  immune  system  in 
controlling cancer initiation is still controversial.  It has 
been shown that immunodeficient mice develop more 
carcinogen-induced and spontaneous cancers than wild-
type  mice  [67,  68].    However,  straightforward 
interpretation  of  studies  on  mice  with  compromised 
adaptive  immunity  is  complicated  by  the  complex 
nature of pro- and anti-tumorigenic interactions with the 
primary  and  adaptive  immune  systems  [69].  
Nonetheless,  mouse  models  have  revealed  that  the 
adaptive  immune  system  is  important  for  the  initial 
elimination of cancer cells, and that T cells play a role 
in equilibrium (the phase where oncogenic cells are not 
detectable) and escape phases (relapse) of certain forms 
of cancers like sarcomas [67].  However, in an inducible 
melanoma  model,  it  was  found  that  tumor-initiated 
inflammation  could  suppress  the  adaptive  immune 
system’s ability to delay the development of aggressive 
melanomas [70].  Therefore, mouse models indicate that 
the adaptive immune system indeed plays a role in the 
control  of  certain  forms  of  cancer;  however, 
inflammation  can  suppress the  protective  roles  of  the 
adaptive  immune  system.    Since  aging  is  associated 
with an inherent increase in inflammation and declining 
adaptive  immune  function,  these  changes  could 
cooperate  to  reduce  adaptive  immunity,  including 
against malignancies, in old age. 
 
For  B  cell  maturation,  cell  intrinsic  and  extrinsic 
changes both contribute to reductions in production and 
function  of  B  cells  [27,  71,  72],  which  could  in  part 
underlie  increased  disease  susceptibility,  reduced 
responses  to  vaccination,  and  increased  cancer 
incidence in aged populations. Prior to their peripheral 
migration  to  secondary  lymphoid  organs,  B  cells 
develop  in  the  bone  marrow,  differentiating  through 
multiple stages [27].  Studies conducted in mice have 
identified decreased frequencies of common lymphoid 
progenitors (CLP)/ early B cell progenitors (EBP), pre-
pro  B  cells,  pro-B  cells,  and  pre-B  cells  in  the  bone 
marrow of old mice [71, 73-75], which are due in good 
measure to cell-intrinsic changes in HSC [36, 50].  In 
vitro studies show that aged mouse pro-B-cells exposed 
to  limiting  interleukin-7  (IL-7)  proliferate  less  than 
young pro-B-cells, despite similar IL-7-receptor (IL-7R) 
expression levels [76, 77]. Moreover, administration of 
antagonistic anti-IL-7 antibody to young mice has been 
shown  to  recapitulate  the  peripheral  B-cell  repertoire 
skewing observed in old mice [78]. Thus, the decrease 
in  B-lymphopoiesis  in  aged  mice  may  partially  be 
attributed to a decrease in the ability of B-progenitors to 
respond to IL-7 stimulation. 
 
In addition to the decrease in the total number of B cells 
found in the periphery of aged mice, their function also 
declines  in  an  age-dependent  manner  (Figure  3)  [23, 
27,  71].    Specifically,  aged  mouse  B  cells  exhibit 
increased production of low affinity antibodies due to 
decreased  isotype  switching.    In  humans,  the  aging-
associated decline in B cell lymphopoiesis appears less 
drastic compared to mice, and it has been demonstrated 
that B cell lymphopoiesis in humans is less dependent 
on IL-7 stimulation [79, 80].  The decline in humoral 
responses in elderly people is attributed to changes in 
the  composition  of  the  cells  comprising  the  B  cell 
repertoire [23, 81, 82].  Fewer naïve B cells are found in 
elderly populations compared to the numbers found in 
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pool by antigen experienced memory cells.  Also, there 
is  a  decrease  in  overall  antibody  affinity  found  in 
elderly populations due to a general isotype switching 
from IgG to IgM antibodies [23, 83, 84].  Although the 
effects  of  aging  on  B-lymphopoiesis  differ  between 
mice  and  humans,  there  is  significant  overlap  in  the 
decline in B cell function found in aged population from 
both species.  While reductions in B-lymphopoiesis in 
old  age  could  contribute  to  reduced  tumor 
immunesurveillance, as will be discussed below, there 
has  been  more  debate  about  the  implications  of 
perturbed B-cell development towards leukemogenesis. 
 
Emerging Models for Aging and Cancer 
 
The  strong association  between  aging  and  cancer  has 
been  a  focus  of  intensive  research,  with  the  current 
paradigm suggesting that the accumulation of oncogenic 
mutations is the rate-limiting step in the initiation and 
progression of cancer [14].  It is also frequently argued 
that  aging  is  in  part  the  consequence  of  organisms 
attempting to repress cancer evolution [1, 14, 26, 85-
90]. In this view, aging and tissue decline limit cancer 
development,  through  telomere  shortening  and  tumor 
suppressor gene action.  Thus, preventing cancer during 
youth  (when  animals  are  most  likely  to  contribute  to 
future  generations)  requires  mechanisms,  such  as 
limited  telomere  maintenance,  which  contribute  to 
aging phenotypes later in life. Thus, aging is thought to 
in part represent a cost of tumor suppression (Figure 
4A). 
 
According to this model, aging-associated events (ie., 
telomere shortening) increase the activation of tumor 
suppressor genes, which inhibits cancer at the expense 
 
 
 
 
of accelerating the aging process [1, 26, 86, 87, 91, 92].  
Indeed, aging-associated reductions in telomere length 
and function activate p53, a critical tumor suppressor 
[26,  93].    Chronic  activation  of  p53  results  in  a 
suppression  of  DNA  replication,  decreased  cellular 
proliferation,  and  ultimately  cellular  senescence  or 
death [89, 94, 95] (however, note that increased p53-
dependent tumor suppression can be obtained without  
accelerated aging [96, 97]).  In addition to p53, 
 
 
 
 
expression of the INK4A locus-encoded p16and Arf  
tumor  suppressor  genes  also  increases  with  age  in 
certain  hematopoietic  compartments  [98].    Moreover, 
increases in p16 and Arf have been shown to contribute 
to the aging-associated decline in lymphopoiesis [98].  
Decreasing the expression of these tumor suppressors in 
aged  lymphoid  progenitors  reverses  the  senescent 
phenotype,  resulting  in  an  increased  susceptibility  to 
transformation  [98].    These  models  provide  evidence 
Figure 4.  Aging, Cancer, and Selection of the Fittest.  (A) Predominant Model.  (B) Adaptive Oncogenesis Model.  See text for 
details. 
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associated  with  aging  in  certain  cellular  populations. 
But  if  tumor  suppressive  mechanisms  are  elevated  in 
aging  tissues,  then  why  is  there  such  a  strong 
association between age and the increased incidence of 
most cancers, and why do interventions that delay aging 
(like  caloric  restriction)  also  delay  cancer  occurrence 
[99]? 
 
The hematopoietic system has been a valuable organ for 
studying the relationship between aging and cancer [2].  
In  humans  (as  for  other  vertebrates),  most  cancers, 
including  some  leukemias,  show  age-dependent 
increases in incidence [2, 7].  The most common form 
of chronic leukemia in elderly people is B-cell chronic 
lymphoblastic  leukemia  (B-CLL)  [100],  and  the  most 
frequent acute leukemia is acute myelogenous leukemia 
(AML) [101].  In addition, leukemias induced by the 
oncogene  Bcr-Abl  (Ph
+),  including  chronic 
myelogenous  leukemia  (CML)  and  Philadelphia 
Chromosome
+  B-cell  acute  lymphoblastic  leukemia 
(Ph
+  B-ALL),  show  age-dependent  increases  in 
incidence [102].  This age-dependence is more striking 
for CML, with the majority of diagnosis occurring in 
individuals over 50 years old [103].  For Ph
+ B-ALLs, 
the average age of diagnosis is 50 [104, 105], and the 
increased incidence with advancing age is less dramatic 
than for CMLs. 
 
The  correlation  of  aging  with  leukemias  has  been 
studied extensively in mouse models [56].  In general, 
these studies argue that the increase in aging-associated 
myeloid  leukemias  in  mice  results  from  aging-
associated impairment of lymphopoiesis and increases 
in myelopoiesis [37, 56, 71, 106].  According to these 
models,  the  decline  in  the  number  and  function  of 
lymphoid  progenitors  reduces  the  probability  of  a  B 
lymphoid progenitor acquiring an oncogenic mutation 
[2, 56, 71, 98].  The increase in myelopoiesis would in 
turn  accelerate  the  possibility  of  acquiring  a 
transforming event in a myeloid progenitor leading to 
the  observed  aging-associated  increase  in  myeloid 
lineage  leukemias.    Also,  these  models  predict  that 
increased expression of tumor suppressor genes in aged 
lymphoid  progenitors  prevents  transforming  events 
from frequently occurring in this lineage. 
 
As myeloid leukemias are common in elderly humans, 
these  investigators  have  argued  that  these  results  are 
consistent  with  leukemia  development  in  the  lineage 
(myeloid) that remains dominant (i.e. more fit) in mice 
[2, 5, 56, 71, 98, 107]. But if the dominant lineage is the 
most leukemogenic, one should expect mice to develop 
myeloid leukemias.  But instead mice mostly develop 
lymphoid  malignancies  in  old  age  [108,  109], 
coinciding  with  the  reduced  fitness  of  lymphoid 
progenitors.  Unlike  mice,  aging  humans  exhibit  pan-
hematopoietic decline, including in the myeloid lineage 
[26,  57].    This  correlates  with  an  increase  in  both 
myeloid (e.g. AML) and lymphoid leukemias (e.g. B-
CLL and Ph
+ ALL) which are common in the elderly.  
Indeed,  a  major  risk  factor  for  AML  are 
myelodysplastic  syndromes  and  other  bone  marrow 
failure  syndromes  (with  reduced  HSC  and  myeloid 
progenitor  fitness),  which  have  been  proposed  to 
increase  selection  for  adaptive  oncogenic  mutations, 
thus  increasing  the  frequency  of  AML  development 
[110].  Thus,  reduced  fitness  in  particular  progenitor 
cells  actually  coincides  with  increased  malignancy 
development with age, and may at least in part explain 
species-specific  differences  in  the  types  of  leukemias 
that develop. 
 
As introduced above, we have proposed an alternative 
model, dubbed Adaptive Oncogenesis, which proposes 
that  youth  and  high  tissue  fitness  are  actually  tumor 
suppressive  [10,  11,  16]  (Figures  2  and  4B).    This 
model postulates that long-lived multicellular organisms 
have  evolved  stem  cell  populations  with  high  fitness, 
not only as a means of efficiently maintaining a tissue, 
but also because high fitness in a cell population will 
oppose  somatic  cell  evolution.    As  in  animal 
populations  well  adapted  to  their  environments, 
stabilizing selection should limit changes that improve 
fitness in a population of stem cells with high fitness. 
Competition in a young, healthy stem cell pool should 
serve to maintain the status quo, preventing somatic cell 
evolution.  But in stem cell pools impaired by aging or 
other  insults,  the  adaptive  landscape  will  be 
dramatically  altered  [10,  11].  The  fitness  of  the  stem 
cell  pool  will  be  reduced,  allowing  selection  for 
mutations and epigenetic events that improve fitness of 
somatic cells.  We postulate that, from an evolutionary 
biological  perspective,  aging  is  associated  with 
increased  cancer  incidence  because  there  is  minimal 
selection  against  cancer  at  ages  where  an  animal  is 
unlikely to contribute to future generations. 
 
We  recently  obtained  support  for  this  model  in  the 
context  of  Bcr-Abl-initiated  leukemias  in  aged 
hematopoietic systems [40].  Consistent with previous 
studies,  we  showed  that  aging  results  in  decreased 
hematopoietic  progenitor  cell  fitness,  exhibited  by  a 
reduction  in  HSC  frequency  and  decreased  B-
lymphopoiesis.    Pro-  and  pre-  B  cell  progenitors 
isolated from aged mice exhibited defective activation 
of Akt and STAT5, which lie downstream of the IL-7R. 
In contrast, the phosphorylation of STAT3 and Erk was 
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isolated from young mice, indicating that there is not a 
general  decrease  in  all  signaling  pathways  in  old  B-
progenitors.   The  expression  of  Bcr-Abl  in  old  mice, 
and in mice under IL-7-neutralized conditions, restored 
kinase signaling to Akt and STAT5 .  This leads to an 
increased selection of Bcr-Abl expressing cells within 
B-progenitor  pools,  and  ultimately  increased 
leukemogenesis in vivo [40]. Notably, the expansion of 
Bcr-Abl-expressing  cells  within  aged  B-progenitor 
pools  can  be  countered  by  transplantation  of  young 
competitors,  highlighting  the  importance  of 
hematopoietic  progenitor  pool  fitness  in  preventing 
leukemia.  Moreover,  the  early  expansion  of  Bcr-Abl-
expressing  progenitors  in  aged  lymphoid  progenitor 
populations  is  polyclonal,  and  thus  pre-accumulated 
oncogenic mutations in old progenitors are unlikely to 
account  for  age-dependent  selection  for  Bcr-Abl 
expression (but note that a different study showed that 
the age of the target cell for Bcr-Abl induced B-ALLs 
does contribute to age-dependence [111]). Instead, since 
aging  results  in  reduced  receptor-mediated  kinase 
signaling in B-progenitors, and Bcr-Abl expression can 
restore this signaling, we would argue that an important 
contribution  of  aging  towards  Bcr-Abl-initiated 
leukemogenesis is the increased selection for Bcr-Abl in 
signaling-deficient B-progenitor pools [40]. 
 
Thus, we propose that in young lymphoid progenitors, 
efficient receptor signaling (such as via IL-7R) provides 
the  “right  amount”  of  activation  of  downstream 
effectors  for  optimal  B-progenitor  fitness.  In  this 
context, the activation of downstream effectors by Bcr-
Abl  would  lead  to  excessive  signaling,  beyond  the 
levels  needed  for  optimal  fitness.  But  in  old  B-
progenitors,  receptor  signaling  is  deficient,  and  thus 
Bcr-Abl  would  be  adaptive,  in  part  by  increasing 
signaling via effectors shared by receptors like the IL-
7R.  To  put  it  simply,  the  reduced  fitness  of  aged 
progenitor cell pools creates “room for improvement”. 
 
CONCLUSION 
 
The  increasing  proportion  of  elderly  people  in 
populations worldwide and associated increases in rates 
of  cancers  pose  substantial  challenges  to  biomedical 
research  and  medical  care,  making  the  task  of 
deciphering mechanisms linking the two a top priority.  
Since  cancer  is  generally  considered  a  disease  of  the 
elderly,  a  more  comprehensive  understanding  of  how 
aging  alters  cellular  function,  and  how  alterations  in 
cells  and  tissues  impact  on  carcinogenesis,  should 
contribute  to  the  development  of  more  efficacious 
therapeutic and prevention strategies for cancer [112].  
Studies in mice and humans have revealed that aging is 
characterized  by  drastic  reductions  in  immune  cell 
function,  which  subsequently  leads  to  decreased 
immune surveillance.  This immunocompromised state 
has  mainly  been  attributed  to  alterations  in  HSC  and 
hematopoietic  development  (and  in  some  cases  cell 
numbers),  and  aging-associated  thymic  involution.  
Deficiencies  in  these  compartments  result  in  reduced 
myeloid  and  lymphocyte  cellular  functions  and 
decreased  T  and  B  cell  diversity  in  the  periphery.  
Importantly,  aging  is  also  associated  with  increased 
incidence  of  many  cancers,  including  hematopoietic 
malignancies, and in this review we have discussed the 
many possible connections between aging and cancers. 
 
The  most  widely  accepted  explanation  for  the 
association  between  aging  and  cancer  is  that 
accumulating  oncogenic  mutations  (and  epimutations) 
with  age  should  facilitate  cancer  evolution.    Thus, 
according to this view, cancer development is limited 
primarily by the accumulation of oncogenic mutations. 
But just as species evolution is driven by both mutation 
and  selection,  altered  selection  pressures  with  age 
should also contribute to oncogenesis.  Thus, the aged 
microenvironment  should  present  a  different  adaptive 
landscape  relative  to  a  young  microenvironment.  
Mutation  and  selection  centric  explanations  are  not 
mutually exclusive; instead they can be expected to act 
in parallel to contribute to the increase rates of cancers 
with old age. Both aging and cancer are highly complex 
and their causes are certainly multifactorial, and models 
to explain their clear association will also need to be 
multifaceted.  We have reviewed the various changes 
within  the  hematopoietic  system  with  aging  that  are 
expected to contribute to increased cancer incidence in 
the  elderly,  including  accumulating  mutations  and 
epigenetic changes, increased inflammation, decreased 
adaptive  immunity,  altered  numbers  and  fitness  of 
progenitors, and other alterations that could change the 
adaptive landscape. 
 
Exciting recent finding suggest that at least some of the 
effects  of  aging  are  not  irreversible,  as  previously 
thought, and it is possible to rejuvenate cells and tissues 
[92, 113]. Beyond the obvious potential health benefits 
of the reversal of age-dependent tissue regeneration, the 
ability  to  rejuvenate  tissues  should  also  allow 
researchers  to  disentangle  mutational  and  selection 
components in age-related increases in cancers. If the 
selection  component  plays  a  major  role  in  the  age-
related spike in cancers, one should expect decreases in 
cancer  rates  upon  reversal  of  tissue  degeneration.  A 
clearer understanding for how aging-associated changes 
within  the  hematopoietic  system  influence  cancer 
development will be essential for the development of 
preventative and therapeutic strategies. 
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